EDITORIAL   |  December 6, 2019   FDA Grants Priority Review to Pemigatinib for Subgroup The FDA has granted a priority review to a new drug application for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. Read more ADVERTISEMENT Proven portfolio of tests + services, that’s our Foundation. Our portfolio of genomic tests & services is designed for cancer patients at any line of therapy, with proven utility for clinical decision making. Rx only; advanced cancer; doesn’t guarantee treatment match. Learn More     Phase III HLX02 Study Meets Primary End Point in Patients with HER2+ Breast Cancer A multi-center phase III study reported that the trastuzumab biosimilar, HLX02, met its primary end point of best overall response rate (ORR) at week 24. Read more

ICYMI: David Braun, MD, PhD, on the Unique Experiences at IKCS The Dana-Farber Cancer Institute expert discussed the integration of fields and how they yield a unique experience at the International Kidney Cancer Symposium. Read more